SG11201811580SA - Compositions, devices, and methods for the treatment of alcohol use disorder - Google Patents
Compositions, devices, and methods for the treatment of alcohol use disorderInfo
- Publication number
- SG11201811580SA SG11201811580SA SG11201811580SA SG11201811580SA SG11201811580SA SG 11201811580S A SG11201811580S A SG 11201811580SA SG 11201811580S A SG11201811580S A SG 11201811580SA SG 11201811580S A SG11201811580S A SG 11201811580SA SG 11201811580S A SG11201811580S A SG 11201811580SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- floor
- methods
- alcohol use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Mechanical Engineering (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 December 2017 (28.12.2017) WIPO I PCT o 1E1 olo VIII Holm o Hum! oil oimiE (10) International Publication Number WO 2017/223566 Al (51) International Patent Classification: A61K 31/33 (2006.01) A61P 25/32 A61K 31/395 (2006.01) A61P 25/30 A61M 11/00 (2006.01) A61P 25/00 (2006.01) (2006.01) (2006.01) (21) International Application Number: PCT/US2017/039300 (22) International Filing Date: Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) 26 June 2017 (26.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/354,465 24 June 2016 (24.06.2016) US 62/419,736 09 November 2016 (09.11.2016) US (71) Applicant: OPIANT PHARMACEUTICALS, INC. [US/US]; 401 Wilshire Blvd., 12th Floor, Santa Monica, CA 90401 (US). (72) Inventors: CRYSTAL, Roger; 401 Wilshire Blvd., 12th Floor, Santa Monica, CA 90401 (US). AGRAWAL, Arvind; 401 Wilshire Blvd., 12th Floor, Santa Monica, CA 90401 (US). (74) Agent: HATHAWAY, Cynthia; Global Patent Group, LLC, 17014 New College Avenue, Ste 201, St. Louis, MO 63040 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). N (54) Title: COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF ALCOHOL USE DISORDER 1-1 0 (57) : Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition \" comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug 0 products are also provided.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662354465P | 2016-06-24 | 2016-06-24 | |
US201662419736P | 2016-11-09 | 2016-11-09 | |
PCT/US2017/039300 WO2017223566A1 (en) | 2016-06-24 | 2017-06-26 | Compositions, devices, and methods for the treatment of alcohol use disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811580SA true SG11201811580SA (en) | 2019-01-30 |
Family
ID=60784803
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202013034QA SG10202013034QA (en) | 2016-06-24 | 2017-06-26 | Compositions, devices, and methods for the treatment of alcohol use disorder |
SG11201811580SA SG11201811580SA (en) | 2016-06-24 | 2017-06-26 | Compositions, devices, and methods for the treatment of alcohol use disorder |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202013034QA SG10202013034QA (en) | 2016-06-24 | 2017-06-26 | Compositions, devices, and methods for the treatment of alcohol use disorder |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190209464A1 (en) |
EP (1) | EP3474842A4 (en) |
JP (2) | JP2019520361A (en) |
KR (2) | KR102634829B1 (en) |
CN (1) | CN109789122A (en) |
AU (2) | AU2017281941A1 (en) |
CA (1) | CA3028731A1 (en) |
MX (2) | MX2018015985A (en) |
PH (1) | PH12018502738A1 (en) |
RU (2) | RU2022103366A (en) |
SG (2) | SG10202013034QA (en) |
WO (1) | WO2017223566A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017281941A1 (en) * | 2016-06-24 | 2019-02-07 | Aegis Therapeutics Llc | Compositions, devices, and methods for the treatment of alcohol use disorder |
CA3043028A1 (en) * | 2016-11-09 | 2018-05-17 | Opiant Pharmaceuticals, Inc. | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions |
CA3044221A1 (en) * | 2016-11-18 | 2018-05-24 | Opiant Pharmaceuticals, Inc. | Intranasal nalmefene compositions and methods for the treatment of opioid overdose |
US20210220346A1 (en) * | 2018-05-17 | 2021-07-22 | Aegis Therapeutics Llc | Formulations and methods for the prevention of opioid overdose |
WO2020132263A1 (en) * | 2018-12-20 | 2020-06-25 | Aegis Therapeutics, Inc. | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
WO2020230676A1 (en) * | 2019-05-16 | 2020-11-19 | 株式会社新日本科学 | Powder preparation for transnasal administration and method for producing same |
US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
WO2023147443A2 (en) * | 2022-01-26 | 2023-08-03 | Tulex Pharmaceuticals Inc. | Novel compositions |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4882335A (en) * | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
US5069895A (en) * | 1989-11-09 | 1991-12-03 | Diamond Ivan F | Methods for the treatment of alcohol intoxication and dependence |
EP0444778A1 (en) * | 1990-02-14 | 1991-09-04 | Alcon Laboratories, Inc. | Use of alkyl saccharides to enhance the penetration of drugs |
JP2005508888A (en) * | 2001-08-14 | 2005-04-07 | バイオティ セラピーズ コーポレイション | How to treat alcoholism or alcoholism |
US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
US9895444B2 (en) * | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
US20070212307A1 (en) * | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
CA2677205A1 (en) * | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
CA2697990A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
JP5437236B2 (en) * | 2008-04-16 | 2014-03-12 | 一般財団法人化学及血清療法研究所 | Method for producing thrombin-immobilized bioabsorbable sheet preparation |
ES2686299T3 (en) * | 2010-10-29 | 2018-10-17 | Troikaa Pharmaceuticals Ltd | Vitamin B12 nasal compositions |
ME02958B (en) * | 2011-05-13 | 2018-07-20 | Euro Celtique Sa | Intranasal pharmaceutical dosage forms comprising naloxone |
US10485798B2 (en) * | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
US20140171458A1 (en) * | 2012-12-13 | 2014-06-19 | 3B Pharmaceuticals, Inc. | Intranasal naltrexone |
DE202013105715U1 (en) * | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Device for delivering a predetermined amount of a substance to a natural opening of the body |
EP3082817A4 (en) | 2013-12-18 | 2017-06-21 | Aegis Therapeutics, LLC | Compositions for drug administration |
US9480644B2 (en) * | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
AU2017281941A1 (en) | 2016-06-24 | 2019-02-07 | Aegis Therapeutics Llc | Compositions, devices, and methods for the treatment of alcohol use disorder |
-
2017
- 2017-06-26 AU AU2017281941A patent/AU2017281941A1/en not_active Abandoned
- 2017-06-26 RU RU2022103366A patent/RU2022103366A/en unknown
- 2017-06-26 CA CA3028731A patent/CA3028731A1/en active Pending
- 2017-06-26 WO PCT/US2017/039300 patent/WO2017223566A1/en unknown
- 2017-06-26 JP JP2018567665A patent/JP2019520361A/en active Pending
- 2017-06-26 US US16/311,944 patent/US20190209464A1/en not_active Abandoned
- 2017-06-26 KR KR1020227034876A patent/KR102634829B1/en active IP Right Grant
- 2017-06-26 RU RU2019101810A patent/RU2767062C2/en active
- 2017-06-26 EP EP17816377.0A patent/EP3474842A4/en active Pending
- 2017-06-26 MX MX2018015985A patent/MX2018015985A/en unknown
- 2017-06-26 SG SG10202013034QA patent/SG10202013034QA/en unknown
- 2017-06-26 SG SG11201811580SA patent/SG11201811580SA/en unknown
- 2017-06-26 CN CN201780044057.3A patent/CN109789122A/en active Pending
- 2017-06-26 KR KR1020197001264A patent/KR102453781B1/en active IP Right Grant
-
2018
- 2018-12-18 MX MX2022013671A patent/MX2022013671A/en unknown
- 2018-12-21 PH PH12018502738A patent/PH12018502738A1/en unknown
-
2022
- 2022-03-31 JP JP2022058125A patent/JP7492548B2/en active Active
-
2023
- 2023-04-20 AU AU2023202420A patent/AU2023202420A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2767062C2 (en) | 2022-03-16 |
US20190209464A1 (en) | 2019-07-11 |
MX2022013671A (en) | 2022-12-13 |
WO2017223566A1 (en) | 2017-12-28 |
CA3028731A1 (en) | 2017-12-28 |
EP3474842A4 (en) | 2020-01-29 |
JP2019520361A (en) | 2019-07-18 |
AU2023202420A1 (en) | 2023-05-11 |
KR20220167279A (en) | 2022-12-20 |
PH12018502738A1 (en) | 2019-10-21 |
RU2019101810A (en) | 2020-07-27 |
AU2017281941A1 (en) | 2019-02-07 |
KR102634829B1 (en) | 2024-02-07 |
SG10202013034QA (en) | 2021-02-25 |
RU2019101810A3 (en) | 2020-10-14 |
KR102453781B1 (en) | 2022-10-12 |
KR20190055057A (en) | 2019-05-22 |
CN109789122A (en) | 2019-05-21 |
EP3474842A1 (en) | 2019-05-01 |
RU2022103366A (en) | 2022-03-01 |
MX2018015985A (en) | 2019-09-13 |
JP2022088592A (en) | 2022-06-14 |
JP7492548B2 (en) | 2024-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201408174UA (en) | Antibody formulation | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201408261UA (en) | Syringe | |
SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201811237WA (en) | Combination therapies | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof |